Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: ECOG E1609; A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a2b for Resected High Risk Melanoma

 


ECOG E1609; A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a2b for Resected High Risk Melanoma


Trial Focus

Melanoma (Except Eye)

Objective

         This is a clinical trial of ipilimumab that will be administered by IV which is investigational and interferon Alfa-2b that will be administered by IV and is standard of care.

IRB Protocol #

11-0999

Trial Status

Archived

Principle Investigator

KARL LEWIS

Sponsor

ECOG

Contact

GRANT CHAMBERS at (720)848-7135 or GRANT.CHAMBERS@UCDENVER.EDU

Location

ST. MARYS HOSPITAL - G.J. University of Colorado Hospital ST. MARYS HOSPITAL - G.J. University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period to determine eligibility. A treatment period that can last up to 12 to 18 months. A follow up period will consist of clinic visits. // Eligibility criteria include but are not limited to 18 years or older with melanoma.Eligibility criteria include but are not limited to 18 years or older with melanoma.